Role of Fractalkine/CX3CL1 and Its Receptor in the Pathogenesis of Inflammatory and Malignant Diseases with Emphasis on B Cell Malignancies

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left"> </td><td align="center">CX3CR1 (mean% ± SD)</td><td align="center">CX3CL1 (mean% ± SD)</td><td align="center">CHEMOTAXIS assay (<i>n</i>° migrated cases/<i>n</i>° cases)</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">FL</td><td align="center">47.2 ± 12</td><td align="center">48.3 ± 9</td><td align="center">0/10</td></tr><tr><td align="left">MCL</td><td align="center">53.8 ± 10</td><td align="center">58.9 ± 11</td><td align="center">4/14</td></tr><tr><td align="left">MZL</td><td align="center">64 ± 8</td><td align="center">40.2 ± 10</td><td align="center">0/9</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>Expressions of CX3CR1 and CX3CL1 was analyzed on B cells from FL, MCL, or MZL patients by flow cytometry. The results (columns 2 and 3) are expressed as mean percentage positive cells ± SD. Chemotaxis of FL, MCL, and MZL cells was investigated in a transwell assay. In the right column the number (<i>n</i>°) of migrated cases to 300 ng/mL CX3CL1 is shown, in respect to the total number of cases analyzed. <br/></td></tr></table>

Expression and function of CX3CL1/CX3CR1 axis in human B cell lymphomas.

Mediators of Inflammation

tab2

Table 2

Table 2: Role of Fractalkine/CX3CL1 and Its Receptor in the Pathogenesis of Inflammatory and Malignant Diseases with Emphasis on B Cell Malignancies 